Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Jansen

Showing results (221-230 of 254) with videos related to

Pageof 26
Sort By:
Science Translational Medicine|April 6, 2023
Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccineYe Che, Alexey V Gribenko, Xi Song, et al.
The New England Journal of Medicine|September 15, 2021
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3Ann R Falsey, Robert W Frenck, Edward E Walsh, et al.
Clinical and Vaccine Immunology : CVI|November 19, 2010
Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference seraCharles E Rose, Sandra Romero-Steiner, Robert L Burton, et al.
Vaccine|July 13, 2010
Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal diseaseHan-Qing Jiang, Susan K Hoiseth, Shannon L Harris, et al.
The Journal of Infectious Diseases|April 19, 2013
Nonreplicating vaccines can protect african green monkeys from the memphis 37 strain of respiratory syncytial virusJim E Eyles, J Erik Johnson, Shakuntala Megati, et al.
Infection and Immunity|March 21, 2022
Preclinical Immunogenicity and Efficacy of Optimized O25b O-Antigen Glycoconjugates To Prevent MDR ST131 E. coli InfectionsLaurent Chorro, Zhenghui Li, Ling Chu, et al.
Nature|August 14, 2020
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adultsMark J Mulligan, Kirsten E Lyke, Nicholas Kitchin, et al.
Nature|January 20, 2021
Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adultsMark J Mulligan, Kirsten E Lyke, Nicholas Kitchin, et al.
The New England Journal of Medicine|October 14, 2020
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesEdward E Walsh, Robert W Frenck, Ann R Falsey, et al.
Medrxiv : the Preprint Server for Health Sciences|August 26, 2020
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy StudyEdward E Walsh, Robert Frenck, Ann R Falsey, et al.
Pageof 26

Showing results (221-230 of 254) with videos related to

Sort By:
Pageof 26
Science Translational Medicine|April 6, 2023
Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccineYe Che, Alexey V Gribenko, Xi Song, et al.
The New England Journal of Medicine|September 15, 2021
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3Ann R Falsey, Robert W Frenck, Edward E Walsh, et al.
Clinical and Vaccine Immunology : CVI|November 19, 2010
Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference seraCharles E Rose, Sandra Romero-Steiner, Robert L Burton, et al.
Vaccine|July 13, 2010
Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal diseaseHan-Qing Jiang, Susan K Hoiseth, Shannon L Harris, et al.
The Journal of Infectious Diseases|April 19, 2013
Nonreplicating vaccines can protect african green monkeys from the memphis 37 strain of respiratory syncytial virusJim E Eyles, J Erik Johnson, Shakuntala Megati, et al.
Infection and Immunity|March 21, 2022
Preclinical Immunogenicity and Efficacy of Optimized O25b O-Antigen Glycoconjugates To Prevent MDR ST131 E. coli InfectionsLaurent Chorro, Zhenghui Li, Ling Chu, et al.
Nature|August 14, 2020
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adultsMark J Mulligan, Kirsten E Lyke, Nicholas Kitchin, et al.
Nature|January 20, 2021
Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adultsMark J Mulligan, Kirsten E Lyke, Nicholas Kitchin, et al.
The New England Journal of Medicine|October 14, 2020
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesEdward E Walsh, Robert W Frenck, Ann R Falsey, et al.
Medrxiv : the Preprint Server for Health Sciences|August 26, 2020
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy StudyEdward E Walsh, Robert Frenck, Ann R Falsey, et al.
Pageof 26